Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo

Pharmaceutical Research

Volumn 27, Issue 4, 2010, Pages 722-731

  Xiao, Dong ^a,b   Singh, Shivendra Vikram ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Docetaxel; Phenethyl isothiocyanate; Prostate cancer

Indexed keywords

ANDROGEN; DOCETAXEL; PHENETHYL ISOTHIOCYANATE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTHIOCYANATES; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS;

EID: 77953174656     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0079-9     Document Type: Article

References (57)

1. Jemal A, Siegal R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway. J Natl. Cancer Inst. 1994;86:252-254
3. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87:652-661
4. Nelson. WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl. J Med. 2003;349:366-381
5. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology. 2005;19:631-636
6. Labrie F, Dupont A, Belanger A, et al. New approaches in the treatment of prostate cancer: complete instead of partial withdrawal, of androgens. Prostate. 1983;4:579-594
7. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer. What went wrong? J Urol. 2000;164:3-9.
8. Feldman. BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001;1:34-45.
9. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39
10. Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007;67:5117-5125
11. Jin RJ, Lho Y, Connelly L, et al. The nuclear factor-KB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008;68:6762-6769
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Eng J Med. 2004;351:1502-1512
13. Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol. 2007;9 Suppl 2:S3-S12.
14. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66:1022-1037
15. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor KB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005;65:6934-6942
16. Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev. 1996;5:733-748
17. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:795-804.
18. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochem. 2001;56:5-51.
19. Wattenberg LW. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl, isothiocyanate and related compounds. J Natl Cancer Inst. 1977;58:395-398
20. 6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in A/J mouse lung. Cancer Res. 1989;49:2894-2897
21. Stoner GD, Morrissey DT, Heur YH, Daniel EM, Galati AJ, Wagner SA. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res. 1991;51:2063-2068
22. Chen YR, Han J, Kori R, Kong AN, Tan TH. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem. 2002;277:39334-39342
23. Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 2002;62:3615-3619
24. Zhang Y, Tang L, Gonzalez V. Selected, isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther. 2003;2:1045-1052
25. 2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther. 2004;3:567-575
26. Xiao D, Choi S, Lee YJ, Singh SV. Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Mol Carcinog. 2005;43:130-140
27. Xiao D, Zeng Y, Choi S, Lew KL, Nelson JB, Singh SV. Caspase dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable derived cancer chemopreventive agent, is mediated by Bak and Bax. Clin Cancer Res. 2005;11:2670-2679
28. Xiao D, Lew KL, Zeng Y, et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinog. 2006;27:2223-2234
29. Bommareddy A, Hahm ER, Xiao D, et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res. 2009;69:3704-3712
30. Xu C, Shen G, Chen C, Gelinas C, Kong AN. Suppression of NF-kB and NF-kB-regulated gene expression by sulforaphane and PEITC through IkBa, IKK pathway in human prostate cancer PC-3 cells. Oncogene. 2005;24:4486-4495
31. Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vivo and ex vivo. Cancer Res. 2007;67:2239-2246
32. Xiao D, Choi S, Johnson DE, et al. Diallyl trisulfide-induced apoptosis in human, prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated, kinase-mediated phosphorylation of Bcl-2. Oncogene. 2004;23:5594-5606
33. Xiao D, Powolny AA, Singh SV. Benzyl, isothiocyanate targets mitochondrial respiratory chain to trigger ROS-dependent apoptosis in human breast cancer cells. J Biol Chem. 2008;283:30151-30163
34. Xiao D, Srivastava SK, Lew KL, et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G7/M arrest and inducing apoptosis. Carcinog. 2003;24:891-897
35. Xiao D, Lew KL, Kim Y, et al. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Clin Cancer Res. 2006;12:6836-6843
36. Singh SV, Mohan RR, Agarwal R, et al. Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated, with inhibition of p21H-ras processing. Biochem Biophys Res Commun. 1996;225:660-665
37. Singh SV, Powolny AA, Stan SD, et al. Garlic constituent diallyl trisulfide prevents development of poorly-differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res. 2008;68:9503-9511
38. 2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res. 2005;11:6065-6074
39. Howard EW, Lee DT, Chiu YT, Chua CW, Wang X, Wong YC. Evidence of a novel Docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. Int J Cancer. 2008;122:1941-1948
40. Hecht SS, Kenney PMJ, Wang M, Trushin N, Upadhyaya P. Effects of Phenethyl isothiocyanate and benzyl isothiocyanate, individually and in combination, on lung tumorigenesis induced in A/J mice by benzo [ajpyrene and 4-methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett. 2000;150:49-56.
41. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351: 1513-1520
42. Ji Y, Morris ME. Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. Anal Biochem. 2003;323:39-47.
43. Liebes L, Conaway CC, Hochster H, et al. High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem. 2001;291:279-289
44. Ji Y, Kuo Y, Morris ME. Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res. 2005;22:1658-1666
45. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci. 2009; 1171:59-76.
46. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate. 2000;42:186-195
47. kip1 regulation in. LNCaP and PC346 cells. Prostate. 2006;66:749-760
48. Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev. 2006;32:166-179
49. Patterson SG, Wei S, Chen X, et al. Novel role of Stat1 in the development of Docetaxel resistance in prostate tumor cells. Oncogene. 2006;25:6113-6122
50. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by Docetaxel and promotes survival of Docetaxel-treated prostate cancer cells. J Biol Chem. 2008;283:20635-20644
51. Eckelman BP, Salvessen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988-994
52. Dean EJ, Ranson M, Blackhall F, Dive C. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets. 2007;11:1459-1471
53. Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004;3:699-707.
54. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9:4914-4925
55. Watanabe SI, Miyata Y, Kanda S, et al. Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with, and without neo-adjuvant hormonal therapy. J Cancer Res Clin Oncol. In press, 2010.
56. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosomelinked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998; 188:211-216
57. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-kB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kB inhibition by PS-1145 enhances docetaxel antitumor activity. Cancer Res. 2006;12:5578-5586